-
Dr. Jiahong Dong: APASL 2025 BEIJING——Drawing a Blueprint for Liver Disease Elimination and Cure Through Multidisciplinary Collaboration
Liver diseases remain a global challenge with complex diagnostic and therapeutic hurdles. Addressing these requires not only pooling the expertise of global specialists but also integrating valuable experiences from both Eastern and Western medical practices.
-
Dr. Peng Yuan: In the Post-CDK4/6i Era, Entinostat Offers New Hope for Patients with HR+/HER2− Advanced Breast Cancer
Breast cancer remains one of the most prevalent malignancies among women worldwide, and its hormone receptor-positive, HER2-negative (HR+/HER2−) subtype accounts for nearly 70% of all cases. In recent years, the combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has become the gold standard for first-line treatment in metastatic settings. However, once progression occurs on…
-
Dr. Jian Zhang: How Emerging HDAC Inhibitors Could Transform the Treatment Landscape of HR+ Breast Cancer
The recent approval in China of the HDAC inhibitor entinostat introduces a novel, precision-targeted approach to breast cancer treatment. Unlike many targeted therapies, entinostat does not require biomarker testing before…
-
Dr. Nanlin Li: Reshaping the Breast Cancer Treatment Landscape — Clinical Practice and Future Outlook of Weekly HDACi Entinostat
On April 24, 2024, a major milestone was achieved in China’s oncology landscape. The National Medical Products Administration (NMPA) granted official approval for entinostat, a domestically developed, selective histone deacetylase…
-
Dr. Ying Wang: Patient-Centered, Simplified Treatment to Optimize Chronic Disease Management — Entinostat Ushers in the Era of Weekly Therapy for HR+ Advanced Breast Cancer
Breast cancer remains the leading malignancy threatening women’s health worldwide. Among its subtypes, hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer is the most common and typically has a better prognosis, having now entered the era of chronic disease management. In the context of long-term, whole-course management—often spanning over a decade—the concept of “patient-centered care” has become central…
-
The First Weekly HDACi Regimen ! Entinostat Approved to Provide a New Potent and Convenient Option for Patients with HR+/HER2- Advanced Breast Cancer
Breast cancer is the most common malignancy among women worldwide, with the HR+/HER2- subtype being one of the most prevalent forms. With the rapid advancement of medical technology and the continuous emergence of new therapies, patient survival has significantly improved, bringing hope to many. Recently, the novel oral HDAC inhibitor entinostat received official approval from…
-
APASL 2025 Beijing Summit Approaches: Exploring New Frontiers in Multidisciplinary Collaboration for Liver Diseases
Dr. Lai Wei: Currently, two-thirds of global viral hepatitis cases are concentrated in Asia, with about half occurring in China. The World Health Organization (WHO) aims to reduce new viral hepatitis infections by 90% and related mortality by 65% by 2030. Thus, contributions from the Asia-Pacific region are pivotal in achieving these elimination goals.
-
2025 SGBCC Best Poster Awards Announced, Four Chinese Experts Crowned!
On March 13, 2025, the “2025 St. Gallen Breast Cancer Conference (SGBCC) Best Poster Awards” were grandly announced. A total of 482 posters were accepted for this year’s SGBCC
Connecting Medical Expertise through Media